Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 12:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 2,796 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

PREVENT HPV-Related Cancers - BootCamp Translation

NCT06290206
Conditions
HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion
Interventions
PREVENT - BCT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hepatocellular Carcinoma
Interventions
conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Conditions
B-cell Malignancies
Interventions
Tirabrutinib, Idelalisib, Entospletinib, Obinutuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Goshen, Indiana • Portland, Oregon
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Conditions
Difficulties Understanding Speech in Noise
Interventions
Transcranial current stimulation, Auditory training
Device · Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
50 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV Infections
Interventions
DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Conditions
Ovarian Cancer
Interventions
Imatinib Mesylate, Docetaxel
Drug
Lead sponsor
Daniela Matei, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
9
States / cities
Galesburg, Illinois • Elkhart, Indiana • Evansville, Indiana + 6 more
Conditions
Endometrial Cancer
Interventions
retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 26 more
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage I, Lung Cancer Stage II, Lung Cancer Stage III
Interventions
Breathe Easier Progressive Web Application
Other
Lead sponsor
University of South Carolina
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Conditions
Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Prexasertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alcohol Use Disorder
Interventions
Brief Family-Involved Treatment (B-FIT), Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Anxiety and Fear, Pain
Interventions
STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents
Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Active, not recruiting Phase 2 Interventional

MPDL3280A With Chemoradiation for Lung Cancer

NCT02525757
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
MPDL3280A, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Completed Phase 1Phase 2 Interventional Results available

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

NCT05275998
Conditions
HIV-1-infection
Interventions
TMB-365/TMB-380
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Oprozomib, Sorafenib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Burlington, California • Denver, Colorado • Miami, Florida + 3 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Fathers and Babies (FAB) Research Study

NCT07893210
Conditions
Perinatal Mental Health, Fathers, Stress Management
Interventions
Fathers and Babies Program, Mothers and Babies Program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pancreatic Cancer
Interventions
multiTAA specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Houston, Texas
Conditions
Opiate Substitution Treatment
Interventions
Standard Medical Management (SMM)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Cardiac Toxicity, Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
7
States / cities
Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more